Option Care Health downgraded by Jefferies with a new price target
$OPCH
Medical/Nursing Services
Health Care
Jefferies downgraded Option Care Health from Buy to Hold and set a new price target of $26.00 from $38.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $27.00 | Buy → Neutral | Goldman |
| 10/31/2024 | $38.00 → $26.00 | Buy → Hold | Jefferies |
| 10/30/2024 | $43.00 → $29.00 | Buy → Neutral | BofA Securities |
| 7/16/2024 | $36.00 | Mkt Outperform | JMP Securities |
| 2/27/2023 | $38.00 | Buy | Jefferies |
| 8/4/2021 | $22.00 → $24.00 | Buy | Canaccord Genuity |
| 7/19/2021 | $20.00 → $25.00 | Neutral → Buy | Goldman Sachs |
BANNOCKBURN, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results and Highlights Net revenue of $1,278.5 million, up 17.0% compared to $1,093.0 million in the third quarter of 2023Gross profit of $256.7 million, or 20.1% of net revenue, up 1.0% compared to $254.3 million, or 23.3% of net revenue, in the third quarter of 2023Net income of $53.9 million, or $0.31 diluted earnings per share, down 4.3% compared to net inco
BANNOCKBURN, Ill., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its third quarter ended September 30, 2024 on Wednesday, October 30, 2024 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call Details Participants can pre-register for the conference call at the following link: https://register.vevent.com/register/BI08e5c12fc6d744c2bb159e0e3b1ebbc4. The call can also be accessed via a live
BANNOCKBURN, Ill., July 31, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results and Highlights Net revenue of $1,227.2 million, up 14.8% compared to $1,069.1 million in the second quarter of 2023Gross profit of $249.4 million, or 20.3% of net revenue, down 0.6% compared to $250.8 million, or 23.5% of net revenue, in the second quarter of 2023Net income of $53.0 million, or $0.30 diluted earnings per share, down 53.6% compared to ne
BANNOCKBURN, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results and Highlights Net revenue of $1,278.5 million, up 17.0% compared to $1,093.0 million in the third quarter of 2023Gross profit of $256.7 million, or 20.1% of net revenue, up 1.0% compared to $254.3 million, or 23.3% of net revenue, in the third quarter of 2023Net income of $53.9 million, or $0.31 diluted earnings per share, down 4.3% compared to net inco
BANNOCKBURN, Ill., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its third quarter ended September 30, 2024 on Wednesday, October 30, 2024 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call Details Participants can pre-register for the conference call at the following link: https://register.vevent.com/register/BI08e5c12fc6d744c2bb159e0e3b1ebbc4. The call can also be accessed via a live
BANNOCKBURN, Ill., July 31, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results and Highlights Net revenue of $1,227.2 million, up 14.8% compared to $1,069.1 million in the second quarter of 2023Gross profit of $249.4 million, or 20.3% of net revenue, down 0.6% compared to $250.8 million, or 23.5% of net revenue, in the second quarter of 2023Net income of $53.0 million, or $0.30 diluted earnings per share, down 53.6% compared to ne
SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)
SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)
SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)
10-Q - Option Care Health, Inc. (0001014739) (Filer)
8-K - Option Care Health, Inc. (0001014739) (Filer)
8-K - Option Care Health, Inc. (0001014739) (Filer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
Goldman downgraded Option Care Health from Buy to Neutral and set a new price target of $27.00
Jefferies downgraded Option Care Health from Buy to Hold and set a new price target of $26.00 from $38.00 previously
BofA Securities downgraded Option Care Health from Buy to Neutral and set a new price target of $29.00 from $43.00 previously
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
New Board Brings Significant and Diverse Experience to Support Company's Growth and Success Riverbed|Aternity (the "Company") today announced that, as part of its recapitalization, which was finalized today, the following seven directors have been appointed to the Company's new Board of Directors (the "Board"). These appointments became effective on December 7, 2021, upon the completion of the Company's recapitalization and voluntary court-supervised process. "We are pleased to welcome our new directors, a group of seasoned, accomplished and respected business leaders who will bring a wide and diverse range of skills to the Riverbed|Aternity Board," said Dan Smoot, President and CEO of Ri
BANNOCKBURN, Ill., July 28, 2021 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health")(NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today that Dr. Seema Kumbhat has joined the Company as Chief Medical Officer. In this newly created role, Dr. Kumbhat will oversee all clinical strategies for the Company, including clinical operations, continuous quality improvement, accreditation, clinically related sales and marketing efforts, and adherence to regulatory requirements. Dr. Kumbhat will also focus on optimizing clinical operations to ensure the Company delivers the highest quality standards, supe
JMP Securities analyst Constantine Davides initiates coverage on Option Care Health (NASDAQ:OPCH) with a Market Outperform rating and announces Price Target of $36.
Barrington Research analyst Michael Petusky maintains Option Care Health (NASDAQ:OPCH) with a Outperform and maintains $38 price target.